Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going.
Drugs Context. 2022; 11DC

Abstract

Inflammatory bowel diseases, comprising ulcerative colitis (UC) and Crohn's disease, are chronic, immune-mediated and progressive inflammatory disorders affecting the gastrointestinal tract. Tofacitinib is the first oral small-molecule Janus kinase (JAK) inhibitor licensed and approved by the National Institute for Health and Care Excellence (NICE) for use in moderately-to-severely active UC after intolerance, inadequate response, or loss of response to conventional treatment or biologic therapy. The pivotal OCTAVE studies demonstrated the efficacy and safety of tofacitinib for the induction and maintenance of remission in UC. A growing body of evidence from real-world data supports the positive clinical and endoscopic benefits observed with tofacitinib treatment in the OCTAVE trials. This narrative review summarizes the current literature regarding the mechanism of action of tofacitinib, data from registrational trials, emerging real-world evidence, and an overview of the most recent safety evidence. We explore evolving treatment paradigms, including the use of tofacitinib in the COVID-19 era, pregnancy and extraintestinal manifestations, as well as the emerging concept of combining tofacitinib with biological therapy. We will also present a brief overview of the next generation of JAK inhibitors in the pipeline.

Links

PMC Free PDF

Authors+Show Affiliations

Liu E

Section of IBD - Division of Gastroenterology, Northern Care Alliance NHS Trust, Manchester, UK.

Aslam N

University College London Hospitals NHS Foundation Trust, London, UK.

Nigam G

Royal Berkshire Hospital NHS Foundation Trust, Reading, UK. Oxford University Clinical Academic Graduate School, University of Oxford, Oxford, UK.

Limdi JK

Section of IBD - Division of Gastroenterology, Northern Care Alliance NHS Trust, Manchester, UK. Manchester Academic Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

Pub Type(s)

Journal Article

Review

Language

eng

PubMed ID

35462642

Citation

Liu, Eleanor, et al. "Tofacitinib and Newer JAK Inhibitors in Inflammatory Bowel Disease-where We Are and Where We Are Going." Drugs in Context, vol. 11, 2022.

Liu E, Aslam N, Nigam G, et al. Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going. Drugs Context. 2022;11.

Liu, E., Aslam, N., Nigam, G., & Limdi, J. K. (2022). Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going. Drugs in Context, 11. https://doi.org/10.7573/dic.2021-11-4

Liu E, et al. Tofacitinib and Newer JAK Inhibitors in Inflammatory Bowel Disease-where We Are and Where We Are Going. Drugs Context. 2022;11 PubMed PMID: 35462642.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going. AU - Liu,Eleanor, AU - Aslam,Nasar, AU - Nigam,Gaurav, AU - Limdi,Jimmy K, Y1 - 2022/04/08/ PY - 2021/11/11/received PY - 2022/03/04/accepted PY - 2022/4/25/entrez PY - 2022/4/26/pubmed PY - 2022/4/26/medline KW - Crohn’s disease KW - Janus kinase inhibitors KW - effectiveness KW - efficacy KW - inflammatory bowel diseases KW - safety KW - tofacitinib KW - ulcerative colitis JF - Drugs in context JO - Drugs Context VL - 11 N2 - Inflammatory bowel diseases, comprising ulcerative colitis (UC) and Crohn's disease, are chronic, immune-mediated and progressive inflammatory disorders affecting the gastrointestinal tract. Tofacitinib is the first oral small-molecule Janus kinase (JAK) inhibitor licensed and approved by the National Institute for Health and Care Excellence (NICE) for use in moderately-to-severely active UC after intolerance, inadequate response, or loss of response to conventional treatment or biologic therapy. The pivotal OCTAVE studies demonstrated the efficacy and safety of tofacitinib for the induction and maintenance of remission in UC. A growing body of evidence from real-world data supports the positive clinical and endoscopic benefits observed with tofacitinib treatment in the OCTAVE trials. This narrative review summarizes the current literature regarding the mechanism of action of tofacitinib, data from registrational trials, emerging real-world evidence, and an overview of the most recent safety evidence. We explore evolving treatment paradigms, including the use of tofacitinib in the COVID-19 era, pregnancy and extraintestinal manifestations, as well as the emerging concept of combining tofacitinib with biological therapy. We will also present a brief overview of the next generation of JAK inhibitors in the pipeline. SN - 1745-1981 UR - https://www.unboundmedicine.com/medline/citation/35462642/Tofacitinib_and_newer_JAK_inhibitors_in_inflammatory_bowel_disease_where_we_are_and_where_we_are_going_ DB - PRIME DP - Unbound Medicine ER -

Tags

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going.Drugs Context. 2022; 11DC